BIOBio-Rad Laboratories, Inc.
$366.40+29% 1Y
$366.40
$241.7152 weeks$390.31
The financials
Bio-Rad Laboratories, Inc. by the numbers
Bio-Rad Laboratories, Inc. (BIO) reported revenue of $651M in Q2 2026 (quarter ended Jun 30, 2026), down 0.1% from the same quarter a year earlier. That came with a gross margin of 53% and net income of $371M (57% of revenue). For the full year FY2025, revenue was $2.58B (+0.7% year on year) and net income $760M. Its largest region in Q2 2026 was United States at $256M, 39% of the disclosed total, just ahead of Europe at 35%. The next results filing is expected around Oct 28, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $651M | $652M | −0.1% |
| Gross profit | $346M | $345M | +0.1% |
| Operating income | $73M | $77M | −5.8% |
| Net income | $371M | $318M | +17% |
| Diluted EPS | $13.85 | $11.67 | +19% |
| Geographic | Revenue | Share |
|---|---|---|
| United States | $256M | 39% |
| Europe | $229M | 35% |
| Asia Pacific | $122M | 19% |
| Americas | $45M | 6.8% |
Business segments
Revenue split by geographic segment, from SEC XBRL filings.
Latest period: Jun 2026Total $651.0M (+9.9%)
Americas grew +8.3% year on yearUnited States -4.3% year on year
Segment Latestquarter on quarteryear on year
- United States$255.5M$255.5Mquarter on quarter +11%year on year -4.3%+11%-4.3%
- Europe$229.2M$229.2Mquarter on quarter +11%year on year +5.5%+11%+5.5%
- Asia Pacific$121.8M$121.8Mquarter on quarter +10%year on year -3.6%+10%-3.6%
- Americas$44.5M$44.5Mquarter on quarter -1.3%year on year +8.3%-1.3%+8.3%
On our screens:Stocks with no debt
Medical Devices
Ranks #22 of 51 by RyuScore